LESLIE P. WEINER, M.D.
Neurology at San Pablo St, Los Angeles, CA

2002014, Oct 3, 2002

Mar 14, 2002

10/098035

Leslie Weiner - Los Angeles CA, US
Minnie McMillan - Los Angeles CA, US

University of southern California

A61K048/00

424/093210

The present invention relates to the application of genetic engineering to provide a treatment of autoimmune disease. This is achieved preferably through the introduction of one or more recombinant genes encoding self antigens which are the target of an autoimmune response. In particular the invention provides a method of designing and constructing a gene encoding an encephalitogenic epitope of proteolipid protein, and to the in vivo expression of the gene product by a recombinant retroviral vector. The expression and secretion of the encephalitogenic epitope ameliorates the histopathological and clinical characteristics of experimental autoimmune encephalomyelitis (EAE) in the mouse model for multiple sclerosis (MS).

2004007, Apr 15, 2004

Feb 5, 2003

10/359397

Leslie Weiner - Los Angeles CA, US
Minnie McMillan - Bradbury, GB

A61K048/00

424/093210

The present invention relates to the application of genetic engineering to provide a treatment of autoimmune disease. This is achieved preferably through the introduction of one or more recombinant genes encoding self antigens which are the target of an autoimmune response. In particular the invention provides a method of designing and constructing a gene encoding an encephalitogenic epitope of proteolipid protein, and to the in vivo expression of the gene product by a recombinant retroviral vector. The expression and secretion of the encephalitogenic epitope ameliorates the histopathological and clinical characteristics of experimental autoimmune encephalomyelitis (EAE) in the mouse model for multiple sclerosis (MS).

6274136, Aug 14, 2001

May 29, 1996

8/654737

Leslie P. Weiner - Los Angeles CA
Minnie McMillan - Bradbury CA

University of Southern California - Los Angeles CA

A61K 4800, C12N 1500, C12N 700

424 9321

The present invention relates to the application of genetic engineering to provide a treatment of autoimmune disease. This is achieved preferably through the introduction of one or more recombinant genes encoding self antigens which are the target of an autoimmune response. In particular the invention provides a method of designing and constructing a gene encoding an encephalogenic epitope of proteolipid protein, and to the in vivo expression of the gene product by a recombinant retroviral vector. The expression and secretion of the encephalogenic epitope ameliorates the histopathological and clinical characteristics of experimental autoimmune encephalomyelitis (EAE) in the mouse model for multiple sclerosis (MS).

8323963, Dec 4, 2012

Jul 17, 2006

11/488524

Leslie P. Weiner - Los Angeles CA, US
Minnie McMillan - Bradbury CA, US

University of Southern California - Los Angeles CA

C12N 5/10, A61K 48/00

435325, 435357, 424 9321

This invention relates to the design and construction of a gene encoding an encephalogenic epitope of proteolipid protein (PLP), design and construction of a gene encoding an encephalogenic epitope of myelin based protein (MBP), to methods of expression of a PLP epitope, to methods of expression of a MBP epitope, to methods of in vivo secretion of a PLP epitope, and to methods of transferring the partial PLP gene to a host to ameliorate the progression of an immune response to self antigens derived from myelin proteins, to methods of in vivo secretion of a MBP epitope, and to methods of transferring the partial MBP gene to a host to ameliorate the progression of an immune response to self antigens derived from myelin proteins.

2004015, Aug 12, 2004

Feb 5, 2004

10/773356

Leslie Weiner - Los Angeles CA, US
Jorge Correale - Buenos Aires, AR

A61K039/00

424/185100

Disclosed are methods and compositions useful for the treatment of autoimmune diseases. Methods for producing vaccines against autoreactive T-cells are disclosed. The vaccines so produced are capable of restoring a degree of immunologic self-tolerance sufficient to slow or halt the progression of autoimmune disorders. In a preferred embodiment of the invention, a vaccine is derived from attenuated autologous autoreactive T-cells that recognize a variety of myelin-derived proteins. Such vaccine compositions are useful for immunologic therapy for the treatment of multiple sclerosis (MS).

2002000, Jan 24, 2002

Sep 17, 1998

09/156509

LESLIE P. WEINER - LOS ANGELES CA, US
JORGE D. CORREALE - BUENOS AIRES, AR

A61K039/395, A61K039/38

424/154100, 424/184100, 424/810000

Disclosed are methods and compositions useful for the treatment of autoimmune diseases. Methods for producing vaccines against autoreactive T-cells are disclosed. The vaccines so produced are capable of restoring a degree of immunologic self-tolerance sufficient to slow or halt the progression of autoimmune disorders. In a preferred embodiment of the invention, a vaccine is derived from attenuated autologous autoreactive T-cells that recognize a variety of myelin-derived proteins. Such vaccine compositions are useful for immunologic therapy for the treatment of multiple sclerosis (MS).